Endogenous opioid peptides: historical aspects

  • H. W. Kosterlitz
Part of the Biological Council book series


This short chapter serves as an introduction to the following contributions on endogenous opioid peptides and gives some of the more important historical developments in the search for an endogenous ligand for the opiate receptors. One general point has attracted our interest for some time, namely the fact that certain alkaloids found in plants have functional correlates in animal tissues. Although there are certain structural similarities between the two classes of compounds, the plant alkaloids are much more resistant to enzymic inactivation in animal tissues than the corresponding compounds of animal origin, and for this reason are often potent neurotoxic agents. Examples of such pairs of compounds are muscarine and muscimol, derived from the toadstool Amanita muscaria, which correspond to the neurotransmitters acetylcholine and γ-aminobutyric acid (GABA), respectively. Other pairs are nicotine and acetylcholine and also ephedrine and noradrenaline. To these may now be added morphine from Papaver somniferum and the class of peptides known as enkephalins and endorphins.


Endogenous Ligand Opiate Receptor Historical Aspect Neurotransmitter Acetylcholine Plant Alkaloid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akil, H., Mayer, D. J. and Liebeskind, J. C. (1972). Cr. hebd. Séanc. Acari Sci. Paris, 274, 3603–05Google Scholar
  2. Hughes, J. (1975). Brain Res., 88, 295–308CrossRefGoogle Scholar
  3. Hughes, J., Kosterlitz, H. W. and Leslie, F. M. (1975a). Br. J. Pharmac, 53, 371–81CrossRefGoogle Scholar
  4. Hughes, J., Smith, T. W., Kosterlitz, H. W., Fothergill, L. A., Morgan, B. A. and Morris, H. R. (1975b). Nature, 258, 577–79CrossRefGoogle Scholar
  5. Kosterlitz, H. W. and Waterfield, A. A. (1975). A. Rev. Pharmac., 15, 29–47CrossRefGoogle Scholar
  6. Kosterlitz, H. W. and Watt, A. J. (1968). Br. J. Pharmac., 33, 266–76Google Scholar
  7. Paton, W. D. M. (1957). Br. J. Pharmac., 12, 119–27Google Scholar
  8. Pert, C. B. and Snyder, S. H. (1973). Science, 179, 1011–14CrossRefGoogle Scholar
  9. Simon, E. J., Hiller, J. M. and Edelman, I. (1973). Proc. natn. Acad. Sci. U.S.A., 70, 1947–49CrossRefGoogle Scholar
  10. Terenius, L. (1973). Acta pharmac. tox., 33, 377–84CrossRefGoogle Scholar
  11. Trendelenburg, P. (1917). Naunyn-Schmiedebergs Arch. exp. Path. Pharmak., 81, 55–129CrossRefGoogle Scholar

Copyright information

© Institute of Biology Endowment Trust Fund 1978

Authors and Affiliations

  • H. W. Kosterlitz
    • 1
  1. 1.Unit for Research on Addictive DrugsUniversity of AberdeenAberdeenUK

Personalised recommendations